SOURCES SOUGHT
A -- Receptor Profiling and Predictive Toxicology
- Notice Date
- 2/14/2018
- Notice Type
- Sources Sought
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800068
- Archive Date
- 3/13/2018
- Point of Contact
- Ejinwaemeonu Ndidi Okeagu, Phone: (301) 443-6677, Andrew Hotaling, Phone: (301) 443-6677
- E-Mail Address
-
ejinwaemeonu.okeagu@nih.gov, hotalingar@mail.nih.gov
(ejinwaemeonu.okeagu@nih.gov, hotalingar@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is seeking capability statements from qualified Small Business organizations (NAICS code 541714. For details of Small Business Size Standards, see www.SBA.gov) having in-house capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems. In addition, an interested organization should have the capacity to perform in vitro predictive toxicology assays. This is a SMALL BUSINESS SOURCES SOUGHT NOTICE to determine the availability of ALL small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUB Zone small businesses, small disadvantaged businesses, women-owned small businesses, and other small businesses). The purpose of the contract is to provide NIDA preclinical discovery programs with a way to screen compounds using a battery of sites that may be alternative mechanisms of action of candidate compounds, or predictive of toxicology. This will facilitate the discovery of novel structural ligands for specified biological targets in the search for medications for the treatment of drug dependence disorders. The mission of the Division of Therapeutics and Medical Consequences (DTMC) is to accelerate the development and approval of new medications in the field of drug abuse. NIDA, DTMC conducts studies to evaluate compounds for their potential use as treatment medications for drug abuse. MANDATORY REQUIREMENTS: Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a Drug Enforcement Administration (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970 at the time of submission of the proposal. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule 1 controlled substances prior to awarding the contract. Many of the compounds that will be tested will come from private sources (e.g., the pharmaceutical industry) that wish to keep information and data confidential (e.g. until patents are filed). In most cases, NIDA will have signed a confidentiality agreement with the provider indicating that the data obtained will not be released without the provider's written permission. For this reason, the Contractor may not publish, present, or otherwise disclose the results of studies on test compounds unless the NIDA COR grants written permission to publish or otherwise disclose this information. Tasks to be performed: Task 1: Receptor Profile Screening (screening a compound at approximately 64 sites) Task 2: Receptor Binding Affinity and/or Functional Activity, (Computing IC50/Ki at sites showing activity in the profile screening or other sites of interest to NIDA); Task 3: Predictive Toxicology and Pharmacokinetic Testing (Cyp450, hERG channel, genotoxicity (Ames test). Task 4: Assay Development (interested organizations may be asked from time to time to submit a proposal to develop an assay not in their current catalog). Interested organizations must demonstrate and document, in the capability statement submitted, extensive experience in the technical area under consideration. Send information relevant and specific, on each of the following qualifications: 1) expertise in evaluation and personnel with the knowledge of, and experience in conducting receptor and enzyme binding and/or functional assays as well as in vitro predictive toxicology including cardiovascular (e.g. hERG Channel) and genetic predictive assays (e.g. Ames test); b) state-of-the-art assay methodologies; 2) equipment, instrumentation, facility, and personnel to perform the Tasks 3) DEA Research Registration for Schedules II to V with the potential to apply for Schedule I if required. THIS IS NOT A REQUEST FOR PROPOSALS: This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. The Government does not intend to award a contract based on responses under this announcement nor otherwise pay for the preparation of any information sent for the Government's use. Any proprietary information should be so marked. All capability statements should provide the following: 1) company name and address; 2) point of contract, 3) phone/fax/email; 4) NAICS Code(s), 5) business size and status; 6) capability information in response to the requirement and qualifications identified in this notice; and 7) types(s) of business, if any (e.g.,: small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), and Historically Underutilized Business Zone (HUBZone). Written capability statements must be submitted to Ndidi Okeagu, whose contact information is provided, NO LATER THAN FEBRUARY 26, 2018. Paper or electronic capability statements will be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800068/listing.html)
- Place of Performance
- Address: 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland 20892-9559, United States, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04822740-W 20180216/180214231247-cecf85a5e63389116909ad220d256f5b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |